Neuropsychiatric Drug Development Summit 2018

Globally it's estimated 1 in 5 people suffer from neuropsychiatric disorders. This figure, combined with drugs that are showing little or no response is making neuropsychiatric disorders a huge unmet clinical need.
The neuropsychiatric drug development field has been stifled for decades by a lack of scientific progress in understanding the brain and costly and challenging clinical trials.

Speakers: Jim Cassella, Niels Plath, Janet Nicholson, Brigitte Robertson, Mickey Matsumoto, Srinivas Rao, Mark Smith, Christopher Missling, Venkatesha Murthy, Eva Kohegyi